Airspan Networks Launches MobileAccess Digital DAS Platform Across Europe, Including the UK February 23, 2026 Proven digital wireless platform enabling seamless public and private network connectivity
Soho Square Capital’s First Unicorn – Netomnia – to Be Acquired by InfraVia, Liberty Global and Telefónica Through Their Existing Joint Venture nexfibre February 23, 2026 Soho Square Capital LLP (“Soho Square”), an investment firm focused on financing established and growing UK and European SMEs, is pleased to confirm its portfolio company Netomnia, the UK’s second largest alternative fibre provider, has announced an agreement to be acquired by InfraVia, Liberty Global and Telefónica. The acquisition, which is subject to customary clearances, [...]
Motive Expands AI Platform to Automate Driver Qualification, Compliance and Workforce Records Management, Saving Teams from Time-Consuming Administrative Work February 23, 2026 New AI-powered Workforce Management capabilities eliminate manual document tracking, reduce compliance risk and help prevent costly downtime
Jensen Partners Named Recruitment Company of the Year: Investor Relations & Asset Raising at the 2026 Private Equity Wire® European Awards February 23, 2026 Recognition highlights the firm’s leadership in capital formation and investor relations recruitment across European private markets
Molecular Instruments Announces Fully Ambient-Temperature HCR™ Pro RNA-ISH on the BOND-III, Setting a New Standard for Clinical Automation February 23, 2026 Release summary: Molecular Instruments launches fully ambient-temperature HCR™ Pro RNA-ISH on the BOND-III, marking a new generation of clinical-grade RNA-ISH designed to reduce heat-driven variability, preserve patient samples, and enable scalable automation in routine pathology workflows.
Lattice Launches Joint Cyber Resilience Reference Kit with EXOR International and TrustiPhi to Simplify Secure Device Development February 23, 2026 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced a Cyber Resilience Reference Kit designed to help industrial and edge device manufacturers accelerate secure system design, developed in collaboration with EXOR International and TrustiPhi. Built on the Lattice MachXO3D™ secure control FPGA, EXOR International’s industrial edge platform, and TrustiPhi’s integrated security orchestration platform, [...]
Toshiba Showcases End-to-End Innovations Shaping What’s Next in Retail at EuroShop 2026 February 23, 2026 At EuroShop, Toshiba showcases intelligent, scalable solutions that combine AI, computer vision, and energy-efficient design to transform the future of retail.
Graphene Launches Authorised Investment Platform for Alpha Investment Office February 23, 2026 Platform delivers regulated infrastructure, custody connectivity and end-to-end investment operations to support Alpha’s growth strategy
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.
AHS Tower Fully Sold During Development, Generating More Than USD 700 Million February 23, 2026 A new commercial landmark on Sheikh Zayed Road underscores market momentum for next-generation workspaces in Dubai.